Vapendavir-d5 (Synonyms: BTA798-d5) |
| Catalog No.GC48242 |
Vapendavir-d5는 Vapendavir로 표시된 중수소입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Vapendavir-d5 is intended for use as an internal standard for the quantification of vapendavir by GC- or LC-MS. Vapendavir is a capsid-binding antiviral agent.1,2 It binds to a pocket in the human rhinovirus (HRV) strain HRV2 VP1 capsid protein and inhibits the cytopathic effects of HRV2 and HRV14 in HeLa Ohio cells (EC50s = 1 and 5 ng/ml, respectively), as well as in a panel of 39 HRV clinical isolates (median EC50 = 7.3 ng/ml).1 Vapendavir inhibits replication in a panel of 21 enterovirus 71 (EV71) isolates with an average EC50 value of 0.7 μM.2
1.Feil, S.C., Hamilton, S., Krippner, G.Y., et al.An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirusACS Med. Chem. Lett.3(4)303-307(2012) 2.Tijsma, A., Franco, D., Tucker, S., et al.The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replicationAntimicrob. Agents Chemother.58(11)6990-6992(2014)
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *